Dopamine receptor expression and function in corticotroph ectopic tumors.

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Dopamine receptor (DR) expression and dopamine agonist (DA) effectiveness remain uncharacterized in neuroendocrine tumors (NETs) associated with ectopic ACTH syndrome (EAS).
• Ectopic ACTH syndrome (EAS) is a rare condition characterized by excessive cortisol production due to non-pituitary tumors.

Purpose of the Study:

• To investigate Dopamine Receptor (DR) expression, particularly the D2 subtype, in NETs linked to EAS.
• To assess the in vivo efficacy of the dopamine agonist (DA) cabergoline for treating EAS.

Main Methods:

• Immunohistochemistry and RT-PCR were employed to evaluate D2 receptor expression in six EAS-associated NETs (four lung, one pancreatic, one thymic).
• Three patients with persistent EAS underwent treatment with cabergoline (3.5 mg/wk for 6 months), with clinical, hormonal, and tumor parameters monitored.

Main Results:

• D2 receptor expression was detected in 83.3% of tumors via immunohistochemistry and confirmed by RT-PCR in all three treated cases.
• Two out of three patients (66.7%) achieved normalized urinary cortisol levels after 3 months of cabergoline treatment, although one experienced treatment escape later.
• D4 receptor and D(2long) isoform expression were also observed, with D(2short) present in one case.

Conclusions:

• Dopamine receptors are expressed in NETs associated with EAS.
• Cabergoline treatment demonstrates potential efficacy in managing cortisol excess in a subset of EAS patients.
• Larger studies are necessary to validate the therapeutic utility of dopamine agonists in EAS.